Stay Informed About Key Developments for Our Company

The Latest Updates as They Happen

As a valued partner in our shared success, you should be the first to know what’s happening across our company. The articles and announcements below offer a comprehensive glimpse into the recent developments that shape our business and growth strategies.

 

News
81 - 90of about 630 News
81 - 90of about 630 News
May 22, 2020
Not intended for U.S. and UK Media
Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancer
READ MORE
May 19, 2020
Nine internationally recognized experts join Sustainability Council
Independent external council to advise Bayer’s Board of Management on consistent implementation of its sustainability targets
READ MORE
May 13, 2020
Not intended for U.S. and UK Media - New ARAMIS Phase III data to be presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program
Nubeqa™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer
READ MORE
May 11, 2020
Not intended for U.S. and UK Media
Bayer to Present Data from Growing Oncology Portfolio at the ASCO20 Virtual Scientific Program
READ MORE
April 28, 2020
CEO Werner Baumann at the Bayer AG Annual Stockholders’ Meeting:
“We’re active in the right businesses”
READ MORE
April 27, 2020
First quarter of 2020:
Bayer: Good start to 2020 – activities marked by COVID-19
READ MORE
April 21, 2020
Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
READ MORE
March 30, 2020
Not intended for U.S. and UK Media
Nubeqa™ (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer
READ MORE
March 29, 2020
Not intended for U.S. and UK Media - New study results add to solid evidence for the efficacy and safety of Rivaroxaban in the prevention of venous thromboembolism:
Rivaroxaban significantly reduced risk of major venous thromboembolism following nonmajor orthopaedic surgery
READ MORE
March 28, 2020
Not intended for U.S. and UK Media - Data from Phase III VOYAGER PAD study published in The New England Journal of Medicine and presented during the American College of Cardiology’s 69th Annual Scientific Session together with World Congress of Cardiology (ACC.20/WCC Virtual)
Xarelto™ 2.5 mg plus aspirin significantly lowered the combined risk of limb ischemia and major cardiovascular events in patients with symptomatic peripheral artery disease post revascularization
READ MORE
81 - 90of about 630 News
81 - 90of about 630 News

 

Subscribe To Our Investor News Email Alerts

Ad-Hoc Releases

Discover Bayer's Latest Ad-Hoc Releases

read more